Entities / Company
LivaNova.
UK business
- Reports this week
- 1
- Active events
- 2
- Connections
- 44
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
A director of LivaNova sold shares of the company on September 10, 2026, as required by an SEC Form 4 filing.Some support1 report
-
Market growth in the medical device sector, driven by cardiovascular disease trends, involving multiple companies like LivaNova, Medtronic, and Philips in Europe.Some support1 report1 development inside
-
LivaNova reported cardiopulmonary revenue growth driven by the European market.Some support1 report
-
A long-term agreement was secured for the supply of critical oxygenator components between LivaNova and Thermo Fisher Scientific.Some support1 report
Gone quiet
No new reports in 90+ days-
LivaNova received rating upgrades and price target increases from multiple firms, including Mizuho, KeyCorp, and Robert W. Baird, on July 1, 2026.Some support1 report
-
Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.Some support2 reports
-
LivaNova is establishing a research collaboration with Vanderbilt Health and holds an adjunct professorship at the University of Pennsylvania.Some support1 report
-
Needham & Company raised its target price for LivaNova, while director Francesco Bianchi sold shares.Some support1 report
-
LivaNova launched its Essenz Perfusion System in multiple international markets, including Europe, China, and the UAE.Some support1 report
-
LivaNova initiated the process to reconsider its coverage status with the Centers for Medicare and Modern Services (CMS).Some support1 report
-
LivaNova is benefiting from the onshoring trend, which coincides with improved legal clarity in Italy.Some support1 report
-
Zacks Investment Research published stock analysis on LivaNova on June 25, 2025.Speculative1 report
-
Maintained a Buy rating on LivaNova PLC on August 4, 2025.Some support2 reports
-
LivaNova is headquartered in London and hosts its Investor Day in New York City.Some support3 reports
-
Market growth driven by ARDS treatment demand involving Pfizer, Gilead Sciences, and LivaNova.Some support1 report
-
LivaNova and St. Jude Medical are global companies operating in the competitive medical device sector.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around LivaNova this week
News at the entities that move LivaNova most-
Needham & Company TransactionalTD Cowen and Needham & Company boosted the price target and gave a 'buy' rating for Ultra Clean.Moves LivaNova
-
Europe StructuralProduction lines are being supplemented to support existing assembly operations involving Europe and Sandpoint.Moves LivaNova
-
SEC StructuralTrust Co of Tennessee filed a document with the SEC on October 18, 2026.Moves LivaNova
-
Mizuho Securities Mentioned togetherMultiple analyst firms, including Needham, Mizuho, and Zacks, issued rating changes and coverage updates for Harmony Biosciences.Moves LivaNova
-
London Shared contextCAA reports anti-Semitic assaults occurring in London.Moves LivaNova
-
New York City Shared contextA documentary featuring Andy Garcia was filmed in New York City.Moves LivaNova
Connections
The 10 strongest of 44, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Needham & Company Transactional
Needham & Company raised its price target for LivaNova on 2026-06-15.
-
Europe Structural
LivaNova derives a significant portion of its revenue from the European market, establishing a structural economic dependency.
-
SEC Structural
LivaNova is subject to mandatory oversight and filing requirements by the U.S. Securities and Exchange Commission (SEC).
-
Vanderbilt Health Operational
The relationship is characterized by an ongoing research collaboration between the two companies.
-
Francesco Bianchi Transactional
Director Francesco Bianchi sold shares of LivaNova.
-
Mizuho Securities Mentioned together
Mizuho Securities coverage of LivaNova included a target price increase from $85.00 to $90.00.
-
London Shared context
LivaNova is headquartered and based in London.
-
Olympus Operational
Both entities are identified as healthcare companies actively competing for investment.
Show all 10 connections
-
University of Pennsylvania Shared context
The relationship is defined by the presence of an adjunct professor based at the University of Pennsylvania.
-
New York City Shared context
LivaNova conducts business and hosts events within the context of New York City.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
2 eventsShow 2 earlier months
July 2026
1 eventJune 2026
12 events- Market growth in the medical device sector, driven by cardiovascular disease trends, involving multiple companies like LivaNova, Medtronic, and Philips in Europe.
- Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.
- LivaNova is establishing a research collaboration with Vanderbilt Health and holds an adjunct professorship at the University of Pennsylvania.
- Needham & Company raised its target price for LivaNova, while director Francesco Bianchi sold shares.
- LivaNova launched its Essenz Perfusion System in multiple international markets, including Europe, China, and the UAE.
- LivaNova initiated the process to reconsider its coverage status with the Centers for Medicare and Modern Services (CMS).
- LivaNova is benefiting from the onshoring trend, which coincides with improved legal clarity in Italy.
- Zacks Investment Research published stock analysis on LivaNova on June 25, 2025.
- Maintained a Buy rating on LivaNova PLC on August 4, 2025.
- LivaNova is headquartered in London and hosts its Investor Day in New York City.
- Market growth driven by ARDS treatment demand involving Pfizer, Gilead Sciences, and LivaNova.
- LivaNova and St. Jude Medical are global companies operating in the competitive medical device sector.